OxyContin OC 5mg – The Complete Medical Guide
Introduction to OxyContin OC 5mg
OxyContin OC 5mg is an extended-release oxycodone formulation classified as a Schedule II controlled substance. As the lowest available strength of the original OxyContin formulation (pre-2010), it is designed for initiating therapy in opioid-tolerant patients requiring around-the-clock pain management. The “OC” designation indicates it lacks modern abuse-deterrent properties, requiring extra prescribing precautions.
Oxycontin OC 5mg
OxyContin OC 5mg is a prescription medication that contains oxycodone, an opioid analgesic, designed to provide long-lasting relief from moderate to severe pain. The “OC” formulation refers to the original controlled-release version of OxyContin, which is engineered to release the medication steadily over time, offering continuous pain relief.
Typically prescribed for chronic pain conditions, OxyContin OC 5 mg is ideal for patients who need around-the-clock pain management. However, due to its potency and risk of misuse, OxyContin should be used only as directed by a healthcare provider.
Key Benefits:
- Provides extended pain relief with controlled-release technology
- Effective for managing chronic pain
- Ideal for patients needing consistent, long-term pain control
Important Considerations:
- Risk of dependence, overdose, and misuse
- Common side effects include constipation, drowsiness, and dizziness
- Do not combine with alcohol or other sedatives
Consult with your doctor to determine if OxyContin OC 5 mg is the right choice for your pain management needs.
Medical Uses & Indications
FDA-Approved Uses
✅ Moderate to severe chronic pain requiring continuous opioid therapy
✅ Initiation of long-term opioid therapy in tolerant patients
✅ Pain uncontrolled by immediate-release opioids
Key Clinical Features
• Formulation: Original controlled-release (non-abuse deterrent)
• Onset: 1-2 hours
• Duration: 12-hour controlled release
• Equianalgesic ratio: 5mg q12h ≈ 7.5mg oral morphine daily
• DEA Classification: Schedule II (High abuse potential)
Pharmacology & Mechanism
Neurochemical Action
• Full μ-opioid receptor agonist
• κ-opioid receptor partial agonist
• Sustained activation of pain modulation pathways
Metabolic Profile
• Hepatic metabolism: CYP3A4 (major), CYP2D6 (minor)
• Active metabolites: Oxymorphone (via CYP2D6)
• Elimination half-life: 4.5-8 hours (ER formulation)
Dosing & Administration
Standard Protocol
• Initial dose for opioid-tolerant patients: 5mg q12h
• Titration: Adjust by 5mg increments every 3-7 days
• Maximum daily dose: 40mg without specialist consultation
Critical Safety Notes
⚠ Not for opioid-naïve patients
⚠ Never crush/chew tablets (immediate 5mg release risk)
⚠ Naloxone co-prescription required
⚠ Daily PDMP monitoring recommended
Safety Profile
Common Adverse Effects
• Constipation (prophylaxis required)
• Nausea/vomiting (30-40%)
• Dizziness/sedation
• Pruritus (20-25%)
Black Box Warnings
❌ High potential for addiction and abuse
❌ Life-threatening respiratory depression
❌ Accidental exposure danger
❌ Neonatal opioid withdrawal syndrome
Risk Mitigation Strategies
Prescribing Safeguards
Documented trial of non-opioid alternatives first
Written opioid treatment agreement
Weekly follow-ups for first month
Random urine drug screens
Patient Education
• Never share medication
• Recognize overdose signs
• Proper storage in locked container
• Avoid all CNS depressants
Clinical Alternatives
For Chronic Pain
• OxyContin OP (abuse-deterrent formulation)
• Xtampza ER (abuse-deterrent oxycodone)
• Morphine sulfate ER
Non-Opioid Options
• Duloxetine (For neuropathic pain)
• Gabapentin
• Interventional pain procedures
Special Population Considerations
| Population | Dosing Adjustment | Monitoring |
|---|---|---|
| Elderly (≥65) | Start with 2.5mg q12h* | Increased fall risk |
| Hepatic impairment | 50% dose reduction | LFT monitoring |
| Renal (CrCl<30) | q18h dosing | Renal function |
| Pediatric | CONTRAINDICATED | – |



Reviews
There are no reviews yet.